



April 3, 2023

Company name: FINDEX Inc.  
Name of representative: Teruo Aibara, President & CEO  
(Securities code: 3649; PRIME Market)  
Inquiries: Takashi Murakami, Finance & Investor Relations, Business Strategy  
(Telephone: +81-3-6271-8959)

### Notice of Changes in Organizational Structure and Assignments of Officers

FINDEX Inc. (the "Company") hereby announces the changes in its organizational structure and assignments of Officers effective on April 1, 2023. The Directors were duly approved at the 38th General Meeting of Shareholders held on March 28, 2023.

#### 1. Changes in Organizational Structure

##### a) Split of System Development Department

The "System Development Department" has now been divided into "Software Package Development," which handles development and improvement of existing products, and "Product Planning & Development," which is responsible for planning and development of new solutions.

##### **【Software Package Development】**

This department specializes in development of packaged medical software used in large hospitals, and standardization and implementation of medical data and electronic medical record, improving and upgrading the Company's core product "Claio", as well as other packaged solutions that have already been marketed.

##### **【Product Planning & Development】**

This department specializes in development of infrastructural technologies to support digital transformation in medical industry, as well as in developing cloud-based products that form a new outpatient care system, connecting patients and hospitals. The team will be developing new products and services to meet future demands.

##### b) Establishment of a new department for customer support

##### **【Customer Support Department】**

Customer Support Department, a new spinoff from "Medical Solutions Department", is a team responsible for handling inquiries from customers, mainly the clinics. The team is dedicated to support challenges of their customers in complying the domestic medical fee regulations, or to provide cyber security solutions.

c) Change in the scope of responsibilities in the Administration Department

The Company's Administration Department was previously responsible for legal, human resources, accounting, finance, and investor relations all together, but finance and investor relations are transferred to the Business Strategy Department, to decentralize these operations and strengthen the function of each business unit.

2. Changes in Assignments of Officers

Directors (effective on April 1, 2023)


Title	Name	Responsibilities
President & CEO	Teruo Aibara	Business Strategy Department
Director	Kohji Kondo	Department Manager of Medical Sales Solutions, and Supervisor of Health Tech Business
Director	Hiroaki Hasegawa	Department Manager of Consulting, and Supervisor of Public Sector Solutions
Director	Riki Miyakawa	Department Manager of Software Package Development, and Supervisor of Medical Business
Director	Akira Ono	Outside Director
Director	Kouji Yamauchi	Audit & Supervisory Committee (Full-Time)
Director	Takashi Kitada	Outside Director, Audit & Supervisory Committee (Part-Time)
Director	Akira Yamada	Outside Director, Audit & Supervisory Committee (Part-Time)

Corporate Officers (effective on April 1, 2023)

Title	Name	Responsibilities
Corporate Officer	Keisuke Kakiuchi	Department Manager of Hospital Sales Solutions
Corporate Officer (New)	Atsushi Fujita	Department Manager of Administration, Legal, Human Resources, and Accounting
Corporate Officer (New)	Takashi Murakami	Finance & Investor Relations
Corporate Officer	Hideaki Mochiduki	Department Manager of Product Planning & Development

【Reference : Organizational Chart (As of April 3, 2023)】

(Underlined are the changes)



Note: This is a translation of the document originally prepared in Japanese. In the event of any discrepancies in words or the like between this document and the original, the original Japanese version shall govern.